EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Melatonin as a Repurposed Drug for Melanoma Treatment

Rachana Pathipaka, Anita Thyagarajan, Ravi P Sahu

Medical Sciences · 2023

DOI: 10.3390/medsci11010009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, 2023. Verfasst von Rachana Pathipaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, USA. Hauptthemen laut MEDLINE: Melatonin, Skin Neoplasms, Pineal Gland, Melanoma, Experimental. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Elsa U. Pardee Foundation, NIH R21.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is the most aggressive type of skin cancer, with a greater risk of metastasis and a higher prevalence and mortality rate. This cancer type has been demonstrated to develop resistance to the known treatment options such as conventional therapeutic agents and targeted therapy that are currently being used as the standard of care. Drug repurposing has been explored as a potential alternative treatment strategy against disease pathophysiologies, including melanoma. To that end, multiple studies have suggested that melatonin produced by the pineal gland possesses anti-proliferative and oncostatic effects in experimental melanoma models. The anticarcinogenic activity of melatonin is attributed to its ability to target a variety of oncogenic signaling pathways, including the MAPK pathways which are involved in regulating the behavior of cancer cells, including cell survival and proliferation. Additionally, preclinical studies have demonstrated that melatonin in combination with chemotherapeutic agents exerts synergistic effects against melanoma. The goal of this review is to highlight the mechanistic insights of melatonin as a monotherapy or combinational therapy for melanoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninSkin NeoplasmsPineal GlandMelanoma, ExperimentalAnimalsSignal Transduction

Stichwörter der Autor:innen

drug repurposingmelanomamelatonin

Substanzen

Melatonin

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, USA.

Förderung

  • NIEHS NIH HHS
  • Elsa U. Pardee Foundation
  • NIH R21

Zitieren

APA

Pathipaka, R., Thyagarajan, A., & Sahu, R. P. (2023). Melatonin as a Repurposed Drug for Melanoma Treatment. Medical Sciences. https://doi.org/10.3390/medsci11010009

Vancouver

Pathipaka R, Thyagarajan A, Sahu RP. Melatonin as a Repurposed Drug for Melanoma Treatment. Medical Sciences. 2023. doi:10.3390/medsci11010009

BibTeX
@article{Pathipaka2023,
  author = {Pathipaka, Rachana and Thyagarajan, Anita and Sahu, Ravi P},
  title = {Melatonin as a Repurposed Drug for Melanoma Treatment},
  journal = {Medical Sciences},
  year = {2023},
  doi = {10.3390/medsci11010009}
}
Kostenlos starten →